• Je něco špatně v tomto záznamu ?

Bladder sparing options for muscle-invasive bladder cancer

E. Laukhtina, M. Moschini, JY. Teoh, SF. Shariat

. 2024 ; 34 (6) : 471-476. [pub] 20240902

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003679

PURPOSE OF REVIEW: This review critically evaluates the current state of bladder-sparing options in muscle-invasive bladder cancer (MIBC) and provides an overview of future directions in the field. RECENT FINDINGS: Bladder-sparing treatments have emerged as viable alternatives to radical cystectomy (RC) for selected patients with MIBC, especially in those who are unfit for RC or elect bladder preservation. Numerous studies have assessed the efficacy of trimodal therapy (TMT), with outcomes comparable to RC in a subgroup of well selected patients. Combining immunotherapy with conventional treatments in bladder-sparing approaches can yield promising outcomes. Current research is making significant progress in optimizing treatment protocols by exploring new combinations of systemic therapy agents, innovative drug delivery methods, and biomarker-based approaches. Furthermore, clinical markers of response are being tested to ensure adequate response assessment. SUMMARY: Bladder preservation promise to offer a viable alternative to RC for selected patients with MIBC with the potential to improve patient quality of life. Careful patient selection and ongoing research are essential to optimize patient selection, response assessment, and salvage strategies. As evidence continues to evolve, the role of bladder preservation in MIBC is likely to expand, providing patients with more treatment options tailored to their needs and preferences.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003679
003      
CZ-PrNML
005      
20250206104615.0
007      
ta
008      
250121s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MOU.0000000000001220 $2 doi
035    __
$a (PubMed)39224913
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
245    10
$a Bladder sparing options for muscle-invasive bladder cancer / $c E. Laukhtina, M. Moschini, JY. Teoh, SF. Shariat
520    9_
$a PURPOSE OF REVIEW: This review critically evaluates the current state of bladder-sparing options in muscle-invasive bladder cancer (MIBC) and provides an overview of future directions in the field. RECENT FINDINGS: Bladder-sparing treatments have emerged as viable alternatives to radical cystectomy (RC) for selected patients with MIBC, especially in those who are unfit for RC or elect bladder preservation. Numerous studies have assessed the efficacy of trimodal therapy (TMT), with outcomes comparable to RC in a subgroup of well selected patients. Combining immunotherapy with conventional treatments in bladder-sparing approaches can yield promising outcomes. Current research is making significant progress in optimizing treatment protocols by exploring new combinations of systemic therapy agents, innovative drug delivery methods, and biomarker-based approaches. Furthermore, clinical markers of response are being tested to ensure adequate response assessment. SUMMARY: Bladder preservation promise to offer a viable alternative to RC for selected patients with MIBC with the potential to improve patient quality of life. Careful patient selection and ongoing research are essential to optimize patient selection, response assessment, and salvage strategies. As evidence continues to evolve, the role of bladder preservation in MIBC is likely to expand, providing patients with more treatment options tailored to their needs and preferences.
650    _2
$a lidé $7 D006801
650    12
$a nádory močového měchýře $x terapie $x patologie $x chirurgie $7 D001749
650    12
$a léčba šetřící orgány $x metody $7 D059351
650    12
$a invazivní růst nádoru $7 D009361
650    12
$a cystektomie $x metody $7 D015653
650    _2
$a výběr pacientů $7 D018579
650    _2
$a močový měchýř $x chirurgie $x patologie $7 D001743
650    _2
$a výsledek terapie $7 D016896
650    _2
$a imunoterapie $x metody $7 D007167
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Moschini, Marco $u Department of Urology, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy
700    1_
$a Teoh, Jeremy Yuen-Chun $u S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Department of Urology, Weill Cornell Medical College, New York, New York $u Department of Urology, University of Texas Southwestern, Dallas, Texas, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan
773    0_
$w MED00001296 $t Current opinion in urology $x 1473-6586 $g Roč. 34, č. 6 (2024), s. 471-476
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39224913 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104611 $b ABA008
999    __
$a ok $b bmc $g 2263438 $s 1239686
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 34 $c 6 $d 471-476 $e 20240902 $i 1473-6586 $m Current opinion in urology $n Curr Opin Urol $x MED00001296
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace